1. Home
  2. FPF vs MESO Comparison

FPF vs MESO Comparison

Compare FPF & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FPF
  • MESO
  • Stock Information
  • Founded
  • FPF 2013
  • MESO 2004
  • Country
  • FPF United States
  • MESO Australia
  • Employees
  • FPF N/A
  • MESO N/A
  • Industry
  • FPF Trusts Except Educational Religious and Charitable
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FPF Finance
  • MESO Health Care
  • Exchange
  • FPF Nasdaq
  • MESO Nasdaq
  • Market Cap
  • FPF 1.2B
  • MESO 1.3B
  • IPO Year
  • FPF N/A
  • MESO N/A
  • Fundamental
  • Price
  • FPF $18.96
  • MESO $16.36
  • Analyst Decision
  • FPF
  • MESO Buy
  • Analyst Count
  • FPF 0
  • MESO 2
  • Target Price
  • FPF N/A
  • MESO $24.00
  • AVG Volume (30 Days)
  • FPF 186.7K
  • MESO 254.9K
  • Earning Date
  • FPF 01-01-0001
  • MESO 08-28-2025
  • Dividend Yield
  • FPF 8.08%
  • MESO N/A
  • EPS Growth
  • FPF N/A
  • MESO N/A
  • EPS
  • FPF N/A
  • MESO N/A
  • Revenue
  • FPF N/A
  • MESO $17,198,000.00
  • Revenue This Year
  • FPF N/A
  • MESO $288.50
  • Revenue Next Year
  • FPF N/A
  • MESO $167.17
  • P/E Ratio
  • FPF N/A
  • MESO N/A
  • Revenue Growth
  • FPF N/A
  • MESO 191.39
  • 52 Week Low
  • FPF $13.91
  • MESO $7.09
  • 52 Week High
  • FPF $18.09
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • FPF 50.94
  • MESO 44.63
  • Support Level
  • FPF $18.75
  • MESO $16.55
  • Resistance Level
  • FPF $19.01
  • MESO $18.94
  • Average True Range (ATR)
  • FPF 0.15
  • MESO 0.56
  • MACD
  • FPF 0.04
  • MESO -0.27
  • Stochastic Oscillator
  • FPF 85.47
  • MESO 2.77

About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: